Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $55,542 | 23 | 85.4% |
| Unspecified | $5,302 | 3 | 8.2% |
| Travel and Lodging | $3,025 | 11 | 4.7% |
| Food and Beverage | $1,168 | 11 | 1.8% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme Corporation | $44,088 | 20 | $0 (2018) |
| Biogen, Inc. | $8,984 | 2 | $0 (2021) |
| Lilly USA, LLC | $5,261 | 5 | $0 (2017) |
| AbbVie, Inc. | $2,969 | 5 | $0 (2018) |
| Janssen Research & Development, LLC | $1,824 | 7 | $0 (2017) |
| Novartis Pharmaceuticals Corporation | $1,034 | 6 | $0 (2017) |
| Eli Lilly and Company | $810.00 | 2 | $0 (2022) |
| Amgen Inc. | $67.92 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $540.00 | 1 | Eli Lilly and Company ($540.00) |
| 2021 | $8,984 | 2 | Biogen, Inc. ($8,984) |
| 2020 | $270.00 | 1 | Eli Lilly and Company ($270.00) |
| 2018 | $21,037 | 14 | Merck Sharp & Dohme Corporation ($18,000) |
| 2017 | $34,207 | 30 | Merck Sharp & Dohme Corporation ($26,088) |
All Payment Transactions
48 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/29/2022 | Eli Lilly and Company | — | — | In-kind items and services | $540.00 | Research |
| Study: ANTI-AMYLOID TREATMENT IN ASYMPTOMATIC ALZHEIMERS DISEASE -A4 STUDY | ||||||
| 05/24/2021 | Biogen, Inc. | — | Consulting Fee | Cash or cash equivalent | $4,491.75 | General |
| 05/24/2021 | Biogen, Inc. | ADUHELM (Biological) | — | Cash or cash equivalent | $4,491.75 | Research |
| Study: Intuition: a Brain Health Study • Category: NEUROLOGY | ||||||
| 07/31/2020 | Eli Lilly and Company | — | — | In-kind items and services | $270.00 | Research |
| Study: ANTI-AMYLOID TREATMENT IN ASYMPTOMATIC ALZHEIMERS DISEASE -A4 STUDY | ||||||
| 08/27/2018 | AbbVie, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,762.50 | General |
| 08/27/2018 | AbbVie, Inc. | — | Travel and Lodging | In-kind items and services | $23.00 | General |
| 08/20/2018 | Merck Sharp & Dohme Corporation | MK-8931 (Drug) | Consulting Fee | Cash or cash equivalent | $400.00 | General |
| Category: NEUROSCIENCE | ||||||
| 07/23/2018 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $67.92 | General |
| 07/21/2018 | AbbVie, Inc. | — | Food and Beverage | In-kind items and services | $84.25 | General |
| 07/21/2018 | AbbVie, Inc. | — | Food and Beverage | In-kind items and services | $69.27 | General |
| 07/21/2018 | AbbVie, Inc. | — | Food and Beverage | In-kind items and services | $29.69 | General |
| 07/03/2018 | Merck Sharp & Dohme Corporation | MK-8931 (Drug) | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| Category: NEUROSCIENCE | ||||||
| 05/14/2018 | Merck Sharp & Dohme Corporation | MK-8931 (Drug) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: NEUROSCIENCE | ||||||
| 04/13/2018 | Merck Sharp & Dohme Corporation | MK-8931 (Drug) | Consulting Fee | Cash or cash equivalent | $3,800.00 | General |
| Category: NEUROSCIENCE | ||||||
| 03/27/2018 | Merck Sharp & Dohme Corporation | MK-8931 (Drug) | Consulting Fee | Cash or cash equivalent | $2,200.00 | General |
| Category: NEUROSCIENCE | ||||||
| 03/14/2018 | Merck Sharp & Dohme Corporation | MK-8931 (Drug) | Consulting Fee | Cash or cash equivalent | $3,200.00 | General |
| Category: NEUROSCIENCE | ||||||
| 02/12/2018 | Merck Sharp & Dohme Corporation | MK-8931 (Drug) | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| Category: NEUROSCIENCE | ||||||
| 01/09/2018 | Merck Sharp & Dohme Corporation | MK-8931 (Drug) | Consulting Fee | Cash or cash equivalent | $2,600.00 | General |
| Category: NEUROSCIENCE | ||||||
| 11/17/2017 | Novartis Pharmaceuticals Corporation | CNP520 (Drug) | Food and Beverage | In-kind items and services | $102.52 | General |
| 11/16/2017 | Merck Sharp & Dohme Corporation | MK-8931 (Drug) | Consulting Fee | Cash or cash equivalent | $1,600.00 | General |
| Category: NEUROSCIENCE | ||||||
| 11/16/2017 | Novartis Pharmaceuticals Corporation | CNP520 (Drug) | Travel and Lodging | In-kind items and services | $465.92 | General |
| 11/16/2017 | Novartis Pharmaceuticals Corporation | CNP520 (Drug) | Food and Beverage | In-kind items and services | $114.99 | General |
| 11/16/2017 | Novartis Pharmaceuticals Corporation | CNP520 (Drug) | Travel and Lodging | Cash or cash equivalent | $21.25 | General |
| 11/15/2017 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $210.00 | General |
| 11/15/2017 | Novartis Pharmaceuticals Corporation | CNP520 (Drug) | Food and Beverage | In-kind items and services | $119.71 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Intuition: a Brain Health Study | Biogen, Inc. | $4,492 | 1 |
| ANTI-AMYLOID TREATMENT IN ASYMPTOMATIC ALZHEIMERS DISEASE -A4 STUDY | Eli Lilly and Company | $810.00 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 1 | 11 | 12 | $1,692 | $637.34 |
All Medicare Procedures & Services
1 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 11 | 12 | $1,692 | $637.34 | 37.7% |
About Dr. Neelum Aggarwal, M.D
Dr. Neelum Aggarwal, M.D is a Neurology healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/02/2007. The National Provider Identifier (NPI) number assigned to this provider is 1154450799.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Neelum Aggarwal, M.D has received a total of $65,037 in payments from pharmaceutical and medical device companies, with $540.00 received in 2022. These payments were reported across 48 transactions from 8 companies. The most common payment nature is "Consulting Fee" ($55,542).
As a Medicare-enrolled provider, Aggarwal has provided services to 11 Medicare beneficiaries, totaling 12 services with total Medicare billing of $637.34. Data is available for 1 year (2021–2021), covering 1 distinct procedure/service records.
Practice Information
- Specialty Neurology
- Location Chicago, IL
- Active Since 03/02/2007
- Last Updated 01/28/2009
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1154450799
Products in Payments
- MK-8931 (Drug) $44,088
- ADUHELM (Biological) $4,492
- CNP520 (Drug) $824.39
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Chicago
Mr. Augusto Miravalle, Md, MD
Neurology — Payments: $1.1M
Adil Javed
Neurology — Payments: $1.0M
Douglas Nordli, Md, MD
Neurology — Payments: $654,190
Dr. Dusan Stefoski, Md, MD
Neurology — Payments: $610,165
Dr. Danny Bega, M.d, M.D
Neurology — Payments: $432,383
Tatyana Simuni, Md, MD
Neurology — Payments: $385,696